cas 317335-15-2|| where to buy methyl 4-(hydroxymethyl)picolinate

Nom du produit:methyl 4-(hydroxymethyl)picolinate

IUPAC Name:methyl 4-(hydroxymethyl)pyridine-2-carboxylate

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM178754-50g	in stock	țțɅƀ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 317335-15-2 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:317335-15-2; Formule moléculaire:C8H9NO3; Point de fusion:-; Code SMILES:O=C(OC)C1=NC=CC(CO)=C1; Densité:

: Numéro de catalogue:CM178754; Poids moléculaire:167.16; Point d'ébullition:; N° Mdl:MFCD09834350; Stockage:Store at room temperature.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: BMF-219; Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.